推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to off-white
溶解性
DMSO: >5 mg/mL
创始人
Merck & Co., Inc., Kenilworth, NJ, U.S.
储存温度
2-8°C
SMILES字符串
CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15
InChI
1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
InChI key
NFHRQQKPEBFUJK-HSZRJFAPSA-N
一般描述
地伐西匹通过化学修饰而衍生自阿斯匹林，具有苯并二氮杂骨架。
应用
地伐西匹在人胚胎肾293T细胞和人胰腺切片中已被用作胆囊收缩素受体1（CCK1R）拮抗剂。
生化/生理作用
地伐西匹是一种CCK1受体拮抗剂。
地伐西匹是一种CCK1（CCK-A）受体拮抗剂和CCK8拮抗剂。
地伐西匹是一种胆囊收缩素受体1（CCK1R）拮抗剂。它可抑制CCK与外周型受体（CCK-A）的结合。地伐西匹可逆转胆囊收缩素八肽（CCK-8）对吗啡的拮抗作用。
特点和优势
该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单， 请单击此处。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 1 Oral
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Development of a CCK1R-membrane nanoparticle as a fish-out tool for bioactive peptides
Staljanssens D, et al.
Peptides, 68, 219-227 (2015)
X-M Wu et al.
Journal of animal physiology and animal nutrition, 96(2), 214-219 (2011-03-29)
Total parenteral nutrition (TPN) results in atrophy of the pancreas, while cholecystokinin (CCK) can significantly stimulate the exocrine pancreas in rodents. This study was designed to examine whether CCK may improve the atrophy of the pancreas in rats on TPN
Kaleeckal G Harikumar et al.
Assay and drug development technologies, 9(4), 394-402 (2011-03-15)
The success in screening for drug candidates is highly dependent on the power of the strategy implemented. In this work, we report and characterize a novel fluorescent benzodiazepine antagonist of the type 1 cholecystokinin receptor (3-(3-(7-fluoro-1-(2-isopropyl(4-methoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)ureido)benzoic acid) that can be
Clémence Blouet et al.
PloS one, 7(12), e51898-e51898 (2012-12-20)
Previous evidence indicates that duodenal lipid sensing engages gut-brain neurocircuits to determine food intake and hepatic glucose production, but a potential role for gut-brain communication in the control of energy expenditure remains to be determined. Here, we tested the hypothesis
Yuki Orikawa et al.
Molecular pain, 6, 72-72 (2010-10-29)
Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine prolonged the survival period in a lethal pancreatic cancer xenograft
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门